High Prevalence of SARS-CoV-2 Antibodies in Care Homes Affected by COVID-19: Prospective Cohort Study, England
Overview
Authors
Affiliations
Background: We investigated six London care homes experiencing a COVID-19 outbreak and found high rates of SARS-CoV-2 infection among residents and staff. Here we report follow-up investigations including antibody testing in the same care homes five weeks later.
Methods: Residents and staff in the initial investigation had a repeat nasal swab for SARS-CoV-2 RT-PCR and a blood test for SARS CoV-2 antibodies using ELISA based on SARS-CoV-2 native viral antigens derived from infected cells and virus neutralisation.
Findings: Of the 518 residents and staff in the initial investigation, 186/241 (77.2%) surviving residents and 208/254 (81.9%) staff underwent serological testing. Almost all SARS-CoV-2 RT-PCR positive residents and staff were seropositive five weeks later, whether symptomatic (residents 35/35, 100%; staff, 22/22, 100%) or asymptomatic (residents 32/33, 97.0%; staff 21/22, 95.5%). Symptomatic but SARS-CoV-2 RT-PCR negative residents and staff also had high seropositivity rates (residents 23/27, 85.2%; staff 18/21, 85.7%), as did asymptomatic RT-PCR negative individuals (residents 61/91, 67.0%; staff 95/143, 66.4%). Neutralising antibody was detected in 118/132 (89.4%) seropositive individuals and was not associated with age or symptoms. Ten residents (10/79 re-tested, 12.7%) remained RT-PCR positive but with higher RT-PCR cycle threshold values; 7/10 had serological testing and all were seropositive. New infections were detected in three residents and one staff.
Interpretation: RT-PCR provides a point prevalence of SARS-CoV-2 infection but significantly underestimates total exposure in outbreak settings. In care homes experiencing large COVID-19 outbreaks, most residents and staff had neutralising SARS-CoV-2 antibodies, which was not associated with age or symptoms.
Funding: PHE.
De Rop L, Vercruysse H, Alenus U, Brusselmans J, Callens S, Claeys M Viruses. 2024; 16(9).
PMID: 39339937 PMC: 11437469. DOI: 10.3390/v16091461.
Analysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020-2021.
Greene M, Smyth P, English A, McLaughlin J, Bucholc M, Bailie J Heliyon. 2024; 10(2):e24184.
PMID: 38304848 PMC: 10830527. DOI: 10.1016/j.heliyon.2024.e24184.
Attribution of nosocomial seeding to long-term care facility COVID-19 outbreaks.
Flannagan J, Chudasama D, Hope R, Collin S, Bhattacharya A, Merrick R Epidemiol Infect. 2023; 151:e191.
PMID: 37876042 PMC: 10728972. DOI: 10.1017/S0950268823001565.
Bautista Balbas L, Sandino Gomez R, Gil Conesa M, Velasco Guijarro O, Rodriguez Caravaca G, Jou Rivera F Workplace Health Saf. 2023; 71(5):229-237.
PMID: 36708002 PMC: 9895301. DOI: 10.1177/21650799221135587.
Joshi K, Rumpler E, Kennedy-Shaffer L, Bosan R, Lipsitch M Vaccine. 2023; 41(11):1864-1874.
PMID: 36697312 PMC: 10075509. DOI: 10.1016/j.vaccine.2022.12.053.